EGFR and head and neck squamous cell carcinoma: Although trials assessing the benefits of EGFR inhibitors in HNSCC patients have been published, the benefits of tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, in advanced HNSCC are still unknown (48).